Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.

Albiges L, et al. Lancet Oncol. 2023;24(8):881-891. 

Cabozantinib plus nivolumab in patients with non–clear cell renal cell carcinoma: updated results from a phase 2 trial.

Fitzgerald KN, et al. Eur Urol. 2024:86(2):90-94.

Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features.

McGregor BA, et al. J Clin Oncol. 2020;38(1):63-70. 

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

Pal SK, et al. Lancet. 2021;397(10275):695-703. 

Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study.

Pal SK, et al. J Clin Oncol. 2021;39(33):3725-3736. 

Phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).

Suárez C, et al. J Clin Oncol. 2023;41(14):2493-2502. 

First-line pembrolizumab plus lenvatinib for non–clear cell renal cell carcinomas (nccRCC): extended follow-up of the phase 2 KEYNOTE-B61 study.

Voss MH, et al. J Clin Oncol. 2024;42(4 suppl 2).